ArticleLeukemia2022
In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
Open access · greenAbstract read
In one paragraph
Article in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- The PRIME trial: An investigator-initiated, multicentre, phase II study of the poly(ADP-ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)-mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes.British journal of haematology · 2026Article
- Modern Concepts in Precision Targeting of Acute Myeloid Leukemia Based on Principles of Molecular Oncology.Cancers · 2026Review
- Resistance to Targeted Therapy in AML: Current Challenges and Emerging Treatment Strategies.Journal of clinical medicine · 2026Review
- Metabolomic Investigation of Myelodysplastic Syndromes, Multiple Myeloma, and Homozygous β-Thalassemia.Cells · 2025Review
- Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia.Cell stem cell · 2025Article
- Article
- IDH mutant high-grade gliomas.Frontiers in molecular neuroscience · 2025Review
- Metabolic dysregulation in myelodysplastic neoplasm: impact on pathogenesis and potential therapeutic targets.Medical oncology (Northwood, London, England) · 2024Review
- Star wars against leukemia: attacking the clones.Leukemia · 2024Review
- Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors-Recent Advances, Challenges and Future Prospects.International journal of molecular sciences · 2024Review
- Comprehensive Immunogenomic Profiling ofJCO precision oncology · 2024Article
- R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription-Replication Conflicts.Cancer research · 2024Article
- Decoding ferroptosis: transforming orthopedic disease management.Frontiers in pharmacology · 2024Review
- Therapeutic targeting of PARP with immunotherapy in acute myeloid leukemia.Frontiers in pharmacology · 2024Review
- The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches.Biochemical Society transactions · 2023Review
- The diversified role of mitochondria in ferroptosis in cancer.Cell death & disease · 2023Review
- Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination.Molecular cell · 2023Article
- 3q26.2/Cancers · 2023Article
- Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.Neuro-oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 3 countries.
Rana Gbyli *Section of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT, 06520, USA.ORCID http://orcid.org/0000-0001-5524-0739
Yuanbin Song *Section of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT, 06520, USA. Songyb@sysucc.org.cn.ORCID http://orcid.org/0000-0001-5580-5998
Wei Liu *Section of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT, 06520, USA.
Yimeng Gao *Section of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT, 06520, USA.ORCID http://orcid.org/0000-0003-2954-2789
Giulia BianconSection of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT, 06520, USA.
Namrata S ChandhokSection of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT, 06520, USA.
Xiaman WangSection of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT, 06520, USA.
Xiaoying FuSection of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT, 06520, USA.
Amisha PatelSection of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT, 06520, USA.
Ranjini SundaramDepartment of Therapeutic Radiology, Yale University, New Haven, CT, 06520, USA.
Toma TebaldiSection of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT, 06520, USA.ORCID http://orcid.org/0000-0002-0625-1631
Padmavathi MamillapalliSection of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT, 06520, USA.
Amer M ZeidanSection of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT, 06520, USA.
Richard A FlavellDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-4461-0778
Thomas PrebetSection of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT, 06520, USA.ORCID http://orcid.org/0000-0002-6872-625X
Ranjit S BindraDepartment of Therapeutic Radiology, Yale University, New Haven, CT, 06520, USA.
Stephanie HaleneSection of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT, 06520, USA. stephanie.halene@yale.edu.ORCID http://orcid.org/0000-0002-2737-9810
Yale Cancer Center · USYale University · USHoward Hughes Medical Institute · USSun Yat-sen University · CNUniversity of Trento · IT
Funding
Yale Cooperative Hematology Specialized Core CenterU54DK106857 · NIDDK · YALE UNIVERSITY · PI JOHN HWA, Diane S Krause · 2015 to 2026
$9.7MTargeting Defective DNA Damage Response Pathways in IDH1/2-mutant AMLR01CA266604 · NCI · YALE UNIVERSITY · PI Ranjit Bindra, Stephanie Halene · 2022 to 2026
$3.3MThe role of mutant splicing factor SRSF2 in MyelodysplasiaR01DK102792 · NIDDK · YALE UNIVERSITY · PI HALENE, STEPHANIE · 2016 to 2019
$1.5MHoward Hughes Medical InstituteNCI NIH HHS R01 CA266604NIDDK NIH HHS R01 DK102792NIDDK NIH HHS U54 DK106857
Abstract
Treatment options for patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are scarce. Recurring mutations, such as mutations in isocitrate dehydrogenase-1 and -2 (IDH1/2) are found in subsets of AML and MDS, are therapeutically targeted by mutant enzyme-specific small molecule inhibitors (IDH
Indexed as
Leukemia, Myeloid, AcuteMyelodysplastic SyndromesEnzyme InhibitorsHumansIsocitrate DehydrogenaseMutationPoly(ADP-ribose) Polymerase InhibitorsRecurrenceEnzyme InhibitorsIDH1 protein, humanIsocitrate DehydrogenasePoly(ADP-ribose) Polymerase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.